Literature DB >> 8279646

Increased in vivo activation of neutrophils and complement in sickle cell disease.

A O Mohamed1, M S Hashim, U R Nilsson, P Venge.   

Abstract

Eight patients with homozygous sickle cell anemia, 15 heterozygotes, and eight control individuals were investigated with respect to plasma concentrations of the inflammatory markers lysozyme and myeloperoxidase and the complement activation marker C3d. The patients showed significantly increased levels of myeloperoxidase and C3d, but not lysozyme, compared with the heterozygotes and the controls. The heterozygotes were also significantly different from the controls with regard to C3d concentration. The concentrations of myeloperoxidase and C3d in plasma showed a significant inverse correlation with the hemoglobin concentration. Myeloperoxidase and C3d showed a significant positive correlation. This suggests a role for the neutrophil and the complement system in the pathophysiology of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279646     DOI: 10.4269/ajtmh.1993.49.799

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Inhibition of myeloperoxidase decreases vascular oxidative stress and increases vasodilatation in sickle cell disease mice.

Authors:  Hao Zhang; Hao Xu; Dorothee Weihrauch; Deron W Jones; Xigang Jing; Yang Shi; David Gourlay; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  J Lipid Res       Date:  2013-08-16       Impact factor: 5.922

Review 2.  Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease.

Authors:  E S Klings; H W Farber
Journal:  Respir Res       Date:  2001-07-13

3.  Melatonin prevents myeloperoxidase heme destruction and the generation of free iron mediated by self-generated hypochlorous acid.

Authors:  Faten Shaeib; Sana N Khan; Iyad Ali; Tohid Najafi; Dhiman Maitra; Ibrahim Abdulhamid; Ghassan M Saed; Subramaniam Pennathur; Husam M Abu-Soud
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.